» Articles » PMID: 18791714

Prognostic Significance of Tumor-infiltrating T-lymphocytes in Primary and Metastatic Lesions of Advanced Stage Ovarian Cancer

Abstract

Purpose: Ovarian cancer patients with intra-tumoral CD3(+) T-lymphocytes in primary tumor tissue have a better prognosis. This study aims to analyze the presence and relative influence of three important T-lymphocyte subsets, tumor-infiltrating CD8(+) cytotoxic T-lymphocytes (CTL), CD45R0(+) memory T-lymphocytes, and FoxP3(+) regulatory T-lymphocytes (Treg), in primary tumor tissue and omental metastases of patients with ovarian cancer.

Experimental Design: The number of CD8(+), CD45R0(+), and FoxP3(+) T-lymphocytes was determined by immunohistochemistry on a tissue micro array containing ovarian tumor tissue and/or omental metastases obtained at primary debulking surgery from 306 FIGO stage I-IV ovarian cancer patients. Immunohistochemistry data were correlated to clinicopathological parameters and survival data.

Results: High number of CD8(+) CTL and a high CD8(+)/FoxP3(+) ratio in ovarian-derived tumor tissue were associated with increased disease-specific survival and proved to be independent prognostic factors in multivariate analyses. In advanced stage patients, the presence of CD8(+) CTL, CD45R0(+) memory T-lymphocytes, FoxP3(+) Treg or a high CD8(+)/FoxP3(+) ratio in ovarian-derived tumor tissue was associated with an increased disease specific survival in univariate analysis, as was the presence of CD45R0(+) memory T-lymphocytes and FoxP3(+) Treg in omental metastases. Furthermore, in advanced stage patients CD8(+) cytotoxic and FoxP3(+) regulatory T-lymphocytes infiltrating ovarian-derived tumor tissue were independent predictors of increased prognosis.

Conclusions: T-lymphocytes infiltrating primary and metastatic ovarian cancer sites are associated with improved prognosis. These associations are especially distinct in advanced stage patients, underlining the potential for immunotherapy as a broadly applicable therapeutic strategy.

Citing Articles

Examining the evidence for immune checkpoint therapy in high-grade serous ovarian cancer.

Connor A, Lyons P, Kilgallon A, Simpson J, Perry A, Lysaght J Heliyon. 2024; 10(20):e38888.

PMID: 39640610 PMC: 11620064. DOI: 10.1016/j.heliyon.2024.e38888.


Th17/Treg cell balance in patients with papillary thyroid carcinoma: a new potential biomarker and therapeutic target.

Huo M, Adeerjiang Y, Abulitipu A, Khan U, Li X, Zhang L Front Oncol. 2024; 14:1325575.

PMID: 39534095 PMC: 11554530. DOI: 10.3389/fonc.2024.1325575.


Exploring tumor microenvironment in molecular subtyping and prognostic signatures in ovarian cancer and identification of SH2D1A as a key regulator of ovarian cancer carcinogenesis.

Guo H, Zhang L, Su H, Yang J, Lei J, Li X Heliyon. 2024; 10(18):e38014.

PMID: 39347397 PMC: 11437944. DOI: 10.1016/j.heliyon.2024.e38014.


Tumor-Infiltrating T Cells in Skin Basal Cell Carcinomas and Squamous Cell Carcinomas: Global Th1 Preponderance with Th17 Enrichment-A Cross-Sectional Study.

Cunha D, Neves M, Silva D, Silvestre A, Nunes P, Arrobas F Cells. 2024; 13(11.

PMID: 38891095 PMC: 11172364. DOI: 10.3390/cells13110964.


Effect of autologous dendritic cell cytokine-induced killer on refractory metastatic colorectal cancer: a matched case-control comparative study.

Chang S, Ke T, Chen W, Shyu W, Jeng L Front Immunol. 2024; 15:1329615.

PMID: 38476223 PMC: 10927724. DOI: 10.3389/fimmu.2024.1329615.


References
1.
Yu P, Fu Y . Tumor-infiltrating T lymphocytes: friends or foes?. Lab Invest. 2006; 86(3):231-45. DOI: 10.1038/labinvest.3700389. View

2.
Vesalainen S, Lipponen P, Talja M, Syrjanen K . Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer. 1994; 30A(12):1797-803. DOI: 10.1016/0959-8049(94)e0159-2. View

3.
Greenlee R, Murray T, Thun M . Cancer statistics, 2001. CA Cancer J Clin. 2001; 51(1):15-36. DOI: 10.3322/canjclin.51.1.15. View

4.
Erdman S, Sohn J, Rao V, Nambiar P, Ge Z, Fox J . CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. Cancer Res. 2005; 65(10):3998-4004. DOI: 10.1158/0008-5472.CAN-04-3104. View

5.
Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S . Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998; 4(7):844-7. DOI: 10.1038/nm0798-844. View